Stockreport

Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD

Ocular Therapeutix, Inc.  (OCUL) 
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ocutx.com
PDF New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI’s unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control [Read more]